ABOS Acumen Pharmaceuticals, Inc.
Financings ·
The S-3 covers common stock, preferred stock, debt securities and warrants, with pricing and terms to come in later prospectus supplements. Acumen's auditor included a going concern paragraph in its report on the 2025 financial statements.
Acumen Pharmaceuticals, Inc. entered into a securities purchase agreement with institutional and accredited investors. RA Capital Management, an existing investor, led the deal, and the release names no placement agent.
Acumen has sold $12.3 million of stock under its sales agreement so far, which leaves $37.7 million available. BofA Securities, Stifel and BTIG are the sales agents.
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a disease-modifying approach aimed at what it believes is a key underlying cause of Alzheimer's disease (AD). The company focuses on soluble amyloid-beta oligomers (AβOs), which it describes as a primary toxin in AD pathology. Its lead candidate, sabirnetug (ACU193), is a recombinant humanized IgG2 monoclonal antibody designed to selectively target AβOs. Sabirnetug is in the Phase 2 ALTITUDE-AD trial, a randomized, double-blind, placebo-controlled study of 542 participants with mild cognitive impairment or mild dementia due to AD, with top-line results expected in late 2026. The Phase 1 INTERCEPT-AD trial in early AD was completed in the second quarter of 2023. The company is also developing a blood-brain barrier-penetrating, AβO-targeted Enhanced Brain Delivery (EBD) therapy under a July 2025 collaboration with JCR Pharmaceuticals, with an IND targeted for mid-2027. A subcutaneous formulation of sabirnetug is being developed under a global collaboration with Halozyme, Inc.
| Product or program | What it is | Stage |
|---|---|---|
| Sabirnetug (ACU193) | Anti-AβO antibody for mild cognitive impairment or mild dementia due to Alzheimer's disease | Phase 2 ALTITUDE-AD; top-line results expected late 2026 |
| Sabirnetug subcutaneous | Subcutaneous formulation of sabirnetug developed with Halozyme | Phase 1 results announced March 2025 |
| EBD therapy | Blood-brain barrier-penetrating AβO-targeted therapy developed with JCR | Preclinical; IND targeted for mid-2027 |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $104.9 million | $93.8 million |
| Net income (loss) | -$121.3 million | -$102.3 million |
| Cash from operations | -$115.5 million | -$86.2 million |
| Cash and equivalents | $54.0 million | $35.6 million |
| Short-term investments | $62.9 million | $135.9 million |
Our latest story on this, dated Oct 26, 2026: "Acumen Pharmaceuticals files a $500,000,000 shelf registration". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Mar 16, 2026: "Acumen Pharmaceuticals agrees to $35.75 million private placement at $3.30 per share". The story links the filing or release it is based on. Read the story.
Acumen Pharmaceuticals, Inc. trades under the ticker ABOS on NASDAQ.
Acumen Pharmaceuticals, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Acumen Pharmaceuticals, Inc. is 1576885. Its filings are on SEC EDGAR.
72,317,285 shares as of 2026-08-07, per the cover page of its 10-Q filed 2026-08-12.
Our directory records Acumen Pharmaceuticals, Inc. under United States.
Our directory classifies Acumen Pharmaceuticals, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Acumen Pharmaceuticals, Inc. is US00509G2093.
aibio.space lists Acumen Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a disease-modifying approach aimed at what it believes is a key underlying cause of Alzheimer's disease (AD). The company focuses on soluble amyloid-beta oligomers (AβOs), which it describes as a primary toxin in AD pathology.
Sabirnetug (ACU193): Anti-AβO antibody for mild cognitive impairment or mild dementia due to Alzheimer's disease Stage: Phase 2 ALTITUDE-AD; top-line results expected late 2026.
Sabirnetug subcutaneous: Subcutaneous formulation of sabirnetug developed with Halozyme Stage: Phase 1 results announced March 2025.
Acumen Pharmaceuticals, Inc. reported a net loss of $121.3 million for the fiscal year ended Dec 31, 2025, and used $115.5 million of cash in operations, per its annual report to the SEC.
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). Source
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio